

Cell Line Data Sheet for CHLA-95

Cell Line Name: CHLA-95

Disease: Neuroblastoma
Phase of Therapy: Post-Chemotherapy (Progressive Disease)
Treatment: N/A
Disease Stage: 4
Gender: Female
Age at diagnosis: NA
Race: N/A
Age at sample collection: N/A
Source of Culture: Bone marrow
Primary Tumor Site: N/A
Date Established: July 1991

MYCN Patient: Amplified
MYCN Cell line: N/A
TH mRNA: Expressed
p53 functionality: N/A
Telomere Mechanism: N/A
ALK: N/A
RNAseq: N/A
WES: N/A

Growth Conditions: Please see Protocols section at <https://www.cccells.org/protocols.php>
 5% CO₂, 20% O₂, 37.0°C

Media Formulation: Please see Protocols section at <https://www.cccells.org/protocols.php>
 Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 278 hours
Growth Properties: Adherent, grow mostly in clumps

STR Profile: May be obtained at <https://strdb.cccells.org/>
Notes: The Childhood Cancer Repository has a matching cell line available from this same patient – CHLA-78.

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis



Cell Line Data Sheet for CHLA-95

Cell Line Name: CHLA-95

References:

1. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. *Cancer Res.* 61, 679-686, 2001. PubMed ID: [11212268](https://pubmed.ncbi.nlm.nih.gov/11212268/)

<https://cancerres.aacrjournals.org/content/61/2/679.long>


2. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer.* 56: 239-249, 2011. PubMed ID: [20922763](https://pubmed.ncbi.nlm.nih.gov/20922763/) (www.PPTPinvitro.org)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>


Cell Line Data Sheet for CHLA-95

Cell Line Name: CHLA-95


(10x magnification)



(10x magnification)



(20x magnification)



(20x magnification)

